Anti-inflammatory effects of topical ocular MAXIDEX administration to rabbits following vitrectomy or lensectomy.
We conducted a series of surgical studies (n=155) to find out the possible utility of the Dutch Belted rabbits as an ocular test model. Following either vitrectomy (n=59) or lensectomy (n=96) studies using either BSS or BSS Plus, we characterized the corresponding magnitude and duration of inflammatory response of selected endpoints over a one-week period. Preoperative Dutch Belted rabbits served as controls for baseline determination (n=27). Inflammatory endpoints included clinical inflammation, blood aqueous barrier (BAB) changes measured by particle-scatter and fluorophotometry, corneal edema, and prostaglandin-E2 (PGE2). Topical ocular 0.1% dexamethasone (MAXIDEX) served as a positive treatment group. We compared the inflammatory features (treated and untreated) to determine significance. Using either irrigating solution, the endpoints (n=101) were shown increased in both models. While the clinical scores were similar following both types of surgery (ns; p=0.51), the lensectomy study caused a more marked effect on corneal edema (p=0.0004) and PGE2 production (p=0.002) compared with the vitrectomy study. After the lensectomy procedure, BSS Plus (n=52) compared with BSS (n=24) showed a significant improvement (p=0.004) of clinical score during the recovery phase. Further improvement was gained over BSS Plus (n=52) using MAXIDEX treatment. Topical MAXIDEX (lensectomy, n=20/group; vitrectomy, n=12/group) reduced clinical score (p<0.001), decreased BAB breakdown to fluorescein (p<0.01), lessened particle flare (p<0.05), inhibited aqueous PGE2 levels (p<0.001), and reduced corneal edema (p=0.01) in the lensectomy group. The use of the rabbit model offers a convenient test to identify therapeutic agents that could lessen ocular complications after these common ocular surgeries.
Scheib
Sally A
SA
Alcon Research Ltd, 6201 S Freeway, Fort Worth, TX 76031, USA.
Garner
William H
WH
D000085:Acetates / Q000627:therapeutic use; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001639:Bicarbonates / Q000627:therapeutic use; D018916:Blood-Aqueous Barrier / Q000187:drug effects; D015715:Corneal Edema / Q000209:etiology / Q000517:prevention & control; D003907:Dexamethasone / Q000627:therapeutic use*; D015232:Dinoprostone / Q000096:biosynthesis; D004195:Disease Models, Animal; D004338:Drug Combinations; D009877:Endophthalmitis / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control; D005123:Eye / Q000378:metabolism; D005938:Glucocorticoids / Q000627:therapeutic use*; D005978:Glutathione / Q000627:therapeutic use; D008903:Minerals / Q000627:therapeutic use; D009883:Ophthalmic Solutions / Q000627:therapeutic use; D018918:Phacoemulsification / Q000009:adverse effects*; D011182:Postoperative Care / Q000379:methods; D011817:Rabbits; D012965:Sodium Chloride / Q000627:therapeutic use; D014821:Vitrectomy / Q000009:adverse effects*
D000085:Acetates; D000893:Anti-Inflammatory Agents; C030660:BSS solution; D001639:Bicarbonates; D004338:Drug Combinations; D005938:Glucocorticoids; D008903:Minerals; D009883:Ophthalmic Solutions; C013003:glutathione-bicarbonate-Ringer solution; D012965:Sodium Chloride; D003907:Dexamethasone; D005978:Glutathione; D015232:Dinoprostone